|
產品描述： XMD17-109 is a novel, specific ERK-5 inhibitor, with an IC50 of 162 nM. |
|
靶點：
ERK5:162 nM (IC50);LRRK2[G2019S]:339 nM (IC50);ERK |
參考文獻：
1. Deng X, et al. Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones. Eur J Med Chem. 2013;70:758-67. 2. Elkins, Jonathan M., et al. X-ray Crystal Structure of ERK5 (MAPK7) in Complex with a Specific Inhibitor. Journal of Medicinal Chemistry (2013), 56(11), 4413-4421. 3. Wilhelmsen K, et al. Extracellular signal-regulated kinase 5 promotes acute cellular and systemic inflammation. Sci Signal. 2015 Aug 25;8(391):ra86. |
|
溶解性：
DMSO : ≥ 100 mg/mL (156.54 mM) |
|
保存條件：
-20℃ |
配置溶液濃度參考：
|
1mg |
5mg |
10mg |
| 1 mM |
1.565 ml |
7.827 ml |
15.654 ml |
| 5 mM |
0.313 ml |
1.565 ml |
3.131 ml |
| 10 mM |
0.157 ml |
0.783 ml |
1.565 ml |
| 50 mM |
0.031 ml |
0.157 ml |
0.313 ml |
|
| 注意： |
部分產品我司僅能提供部分信息，我司不保證所提供信息的權威性，僅供客戶參考交流研究之用。 |
上海工商
危險品化學品經營許可證（不帶存儲）
營業執照(三證合一)
北京